MELBOURNE, Australia, 16 September, 2016: AdAlta Limited (ASX: 1AD), the biotechnology company focused on advancing its lead i-body candidate towards clinical development today announced Chief Scientific Officer Dr Mick Foley will present at the Cambridge Healthtech Institute’s 4th Annual Targeting Ocular Disorders conference on Wednesday September 21 as part of the 14th Annual Discovery of Target conference where he will also present on Thursday September 22 at the Westin Boston Waterfront Hotel in Boston MA USA.
The prestigious international event provides a platform to discuss novel targets and disease pathways, the latest drug delivery methods, and the most promising emerging therapies.
Dr Foley will present the data on AdAlta’s lead candidate AD-114 for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.
A copy of the presentations made by Dr Foley will be available on the company’s website www.adalta.com.au
